Despite racial and ethnic minority groups making up nearly half of the United States population, underrepresentation in clinical trials remains a critical challenge. In an effort to improve clinical trial diversity, researchers at The Ohio State University Wexner Medical Center and College of Medicine partnered with The African American Male Wellness Agency, Genentech Inc., and Pfizer, Inc. to engage with almost 450 community members in 25 states and five countries to create solutions to barriers of access, awareness, discrimination and racism, and workforce diversity.
AstraZeneca and Merckannounced long-term results from the OlympiA phase III trial which showed Lynparza (olaparib) demonstrated sustained, clinically meaningful improvements in overall survival, invasive disease-free survival and distant disease-free survival for people with germline BRCA-mutated HER2-negative high-risk early breast cancer.
